PROGRAM DESCRIPTION:

On January 7-8, 2016 the NCI convened a Clinical Trials Planning Meeting, “Moving Forward in Endometrial Cancer: Designing targeted trials for targeted Endometrial Cancer Populations Using Targeted Agents” at the NCI. The summer 2016 GOG Foundation, Inc. Educational Symposium is based on an updated from this meeting and is titled “Endometrial Cancer: The future of targeted therapy.” The symposium will include noted oncologists and Scientists serving as speakers and moderators. The targeted audiences are members and non-members of the NRG research teams to include: Gynecologic Oncologists, Medical Oncologists, Radiation Oncologists, Pathologists, Scientists, and other MDs engaged in oncology research and/or clinical practice; Oncology Nurses, Nurse-practitioners, and other interested Allied Health professionals. The speakers will focus their presentations on progress to date and future plans and possibilities towards designing targeted trials for targeted endometrial cancer populations using targeted agents.

LEARNING OBJECTIVES: Objectives should be specific to the discussion topic

1. Recognize the potential of p53 as a therapeutic target for endometrial cancer
2. Examine the role of mismatch repair in endometrial cancer
3. Identify the potential of PARP Inhibitors in endometrial cancer trials
4. Analyze how the TCGA can inform future trial opportunities
5. Determine if there might be novel targeted radiation approaches in endometrial cancer
6. Recognize what Phase 0 trials can teach us about endometrial cancer
7. Develop novel Phase II clinical trials for endometrial cancer
8. Distinguish clinical trials selective for serous cancers of the uterus